<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030857</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG4716-CL-102</org_study_id>
    <nct_id>NCT05030857</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects</brief_title>
  <official_title>An Open-label, Fixed Sequence, Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of GLPG4716 on the Pharmacokinetics of Midazolam, a Sensitive Index Substrate of CYP3A4, and to Assess the Effect of Food on the Pharmacokinetics of GLPG4716</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of the administration of multiple doses&#xD;
      of GLPG4716 on the amount of midazolam (MDZ) that gets into the blood when the two drugs are&#xD;
      administered together compared to when midazolam is administered alone. Other objectives of&#xD;
      this study are to evaluate the safety and tolerability of GLPG4716 when administered with&#xD;
      midazolam and assess the amount of GLPG4716 that gets into the blood when administered with&#xD;
      midazolam. This study will also assess the effect of food on the amount of GLPG4716 that gets&#xD;
      into the blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of MDZ</measure>
    <time_frame>From Day 1 pre-dose until Day 15</time_frame>
    <description>To determine the effect of GLPG4716 on the pharmacokinetics (PK) of MDZ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of MDZ</measure>
    <time_frame>From Day 1 pre-dose until Day 15</time_frame>
    <description>To determine the effect of GLPG4716 on the PK of MDZ</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of GLPG4716</measure>
    <time_frame>From Day 1 pre-dose until Day 15</time_frame>
    <description>To assess the effect of food on the PK of GLPG4716.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve over the dosing interval (AUCt) of GLPG4716</measure>
    <time_frame>From Day 1 pre-dose until Day 15</time_frame>
    <description>To assess the effect of food on the PK of GLPG4716.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent (SAEs), and TEAEs leading to treatment discontinuations</measure>
    <time_frame>From Day 1 through study completion, an average of one month</time_frame>
    <description>To evaluate the safety and tolerability of GLPG4716 when co-administered with MDZ</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG4716 and Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG4716</intervention_name>
    <description>From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.</description>
    <arm_group_label>GLPG4716 and Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.</description>
    <arm_group_label>GLPG4716 and Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 18 and 55 years of age (extremes included), on the date of&#xD;
             signing the informed consent form. Female subjects should be of non-childbearing&#xD;
             potential.&#xD;
&#xD;
          -  A body mass index between 18.0 and 30.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Judged to be in good health by the investigator based upon:&#xD;
&#xD;
               -  The results of a medical history&#xD;
&#xD;
               -  Physical examination&#xD;
&#xD;
               -  Vital signs&#xD;
&#xD;
               -  Oxygen saturation&#xD;
&#xD;
               -  12-lead electrocardiogram&#xD;
&#xD;
               -  Fasting clinical laboratory safety tests. Aspartate aminotransferase and alanine&#xD;
                  aminotransferase must be no greater than 1.5x upper limit of normal range and&#xD;
                  total bilirubin no greater than 1x upper limit of normal. Other clinical&#xD;
                  laboratory safety test results must be within the reference ranges or test&#xD;
                  results that are outside the reference ranges need to be considered not&#xD;
                  clinically significant in the opinion of the investigator.&#xD;
&#xD;
        This list only contains the key inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to ingredients of GLPG4716 and/or MDZ&#xD;
&#xD;
          -  History of a significant allergic reaction to ingredients of GLPG4716 and/or MDZ as&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  Treatment with any medication including:&#xD;
&#xD;
               -  Over-the-counter and/or prescription medication&#xD;
&#xD;
               -  Dietary supplements&#xD;
&#xD;
               -  Nutraceuticals, vitamins and/or herbal supplements, and hormonal replacement&#xD;
                  therapy&#xD;
&#xD;
               -  Except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2&#xD;
                  weeks) in the last 2 weeks or 5 half-lives of the drug, whichever is longer,&#xD;
                  prior to the first dosing.&#xD;
&#xD;
        This list only contains the key exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia Rueda-Rincon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galapagos Medical Information</last_name>
    <phone>+3215342900</phone>
    <email>medicalinfo@glpg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Altasciences</name>
      <address>
        <city>Montr√©al</city>
        <zip>QC H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

